A Study on the Correlations of MRP-1 Expression with the Pathogenesis and Prognosis of Colorectal Cancer
Affiliations
Purpose: To investigate the expression level of multidrug resistance-associated protein 1 (MRP-1) and its correlation with prognosis in the pathogenetic process of colorectal cancer.
Methods: 116 patients with colorectal adenocarcinoma and 50 patients with colorectal adenomas were studied. Thirty cut-end normal tissue sections were subjected to immunohistochemical staining, real-time polymerase chain reaction (RT-PCR) and Western blotting, to detect the expression levels of MRP-1 gene and protein in tissues. Besides, the correlations of the expression of MRP-1 in colorectal adenocarcinoma tissues with clinicopathological features and prognosis were analyzed.
Results: MRP-1 was mainly expressed in the cell membrane and cytoplasm in colorectal adenocarcinoma. The positive expression rates of MRP-1 in colorectal adenocarcinoma tissues, colorectal adenoma tissues and normal tissues were 73.28, 46.0 and 20.0%, respectively, showing statistically significant differences (p<0.05). In adenocarcinoma tissues, MRP-1 expression level was associated with the differentiation grade, TNM staging and whether there was lymph node metastasis (p<0.05 in all comparisons). The 5-year survival rates of patients with negatively expressed MRP-1 protein, no lymph node metastasis and high/moderate grade of differentiation as well as in stage I+II were remarkably higher (p<0.01 in all comparisons).
Conclusion: In colorectal adenocarcinoma tissues, the expression of MRP-1 is elevated and patients with negatively expressed MRP-1 have a better prognosis. Therefore, MRP-1 can be a reference indicator for clinical diagnosis and prognosis.
Cellular Compartmentalization, Glutathione Transport and Its Relevance in Some Pathologies.
Vazquez-Meza H, Vilchis-Landeros M, Vazquez-Carrada M, Uribe-Ramirez D, Matuz-Mares D Antioxidants (Basel). 2023; 12(4).
PMID: 37107209 PMC: 10135322. DOI: 10.3390/antiox12040834.
Progress and challenges of multidrug resistance proteins in diseases.
Ding P, Gao Y, Wang J, Xiang H, Zhang C, Wang L Am J Cancer Res. 2022; 12(10):4483-4501.
PMID: 36381332 PMC: 9641395.
Marin J, Monte M, Macias R, Romero M, Herraez E, Asensio M Cancers (Basel). 2022; 14(14).
PMID: 35884584 PMC: 9320734. DOI: 10.3390/cancers14143524.
A critical review on modulators of Multidrug Resistance Protein 1 in cancer cells.
Poku V, Iram S PeerJ. 2022; 10:e12594.
PMID: 35036084 PMC: 8742536. DOI: 10.7717/peerj.12594.
E Silva V, Abdallah E, de Brito A, Braun A, Tariki M, de Mello C Diagnostics (Basel). 2021; 11(3).
PMID: 33809053 PMC: 7999095. DOI: 10.3390/diagnostics11030502.